-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $286

Benzinga·10/07/2026 16:52:12
Diffusion vocale
Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $281 to $286.